Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 12 (3), 214-20

The Effect of Infliximab on Patients With Ulcerative Colitis in Korea

Affiliations

The Effect of Infliximab on Patients With Ulcerative Colitis in Korea

Hyun Il Seo et al. Intest Res.

Abstract

Background/aims: Infliximab was introduced recently as a rescue therapy for ulcerative colitis (UC) patients refractory to conventional treatments such as therapy with 5-amiono salicylic acids (5-ASA), immune modulators, and corticosteroids. However, there is insufficient data about its efficacy and safety in Korea.

Methods: From 7 tertiary referral hospitals, 33 patients who were treated with infliximab for moderate to severe (Mayo score 6-12) UC refractory to conventional treatment were recruited to this study. Clinical remission was defined as a total Mayo score of 2 or lower and every subscore less than 2. Partial response was defined as a decrease of Mayo score at least 3 points from baseline.

Results: Twenty-three patients (69.7%) showed clinical remission and 29 patients (87.8%) showed partial response in the observation period. When the remission and non-remission groups were compared in univariate analysis, only a higher total Mayo score at base line (11.0±0.9 vs. 9.9±1.5; P=0.04) was related to remission. The remission maintenance rate decreased with time in the Kaplan-Meier analysis. Two patients experienced re-remission after the first remission followed by aggravation during infliximab treatment. Three patients stopped infliximab treatment owing to adverse events including rhabdomyolysis, pneumonia, and fever of unknown origin.

Conclusions: If there is no choice except surgery for UC patients refractory to conventional treatment, infliximab is an effective and relatively safe treatment option for these patients in Korea.

Keywords: Efficacy; Infliximab; Safety; Ulcerative colitis.

Conflict of interest statement

Conflict of interest: None.

Figures

Fig. 1
Fig. 1
A schematic clinical course of patients. Schematic overview of the clinical course of UC in the study patients during the observation period, regardless of the number of infliximab injections. The dichotomous status of UC is shown as in remission (+) or not (-).
Fig. 2
Fig. 2
Kaplan-Meier graph of cumulative remission. The graph shows progressive decrease in cumulative remission rate with time during infliximab treatment.

Similar articles

See all similar articles

Cited by 5 PubMed Central articles

References

    1. Staehelin A. Prognosis of ulcerative colitis. Follow-up control of cases from 1942 to 1969. Schweiz Med Wochenschr. 1970;100:580–582. - PubMed
    1. Kim SJ, Cho YK, Rhee JE, Yoon CM. Two cases of ulcerative colitis. Korean J Gastroenterol. 1970;2:29–33.
    1. Yang SK, Hong WS, Min YI, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol. 2000;15:1037–1042. - PubMed
    1. Choi CH, Kim YH, Kim YS, et al. Guidelines for the management of ulcerative colitis. Korean J Gastroenterol. 2012;59:118–140. - PubMed
    1. Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46:S59–S65. - PubMed
Feedback